No black box warning on record for Dovato

As of the latest FDA labeling reviewed, Dovato (DOLUTEGRAVIR SODIUM AND LAMIVUDINE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Dovato medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported with dolutegravir. Discontinue DOVATO immediately if signs or symptoms of hypersensitivity reactions develop, as a delay in stopping treatment may result in a life-threatening reaction. ( 5.2 ) • Hepatotoxicity has been

No black box warning on record for Dovato

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Hypersensitivity reactions characterized by rash, constitutional findings, and sometimes organ dysfunction, including liver injury, have been reported with dolutegravir. Discontinue DOVATO immediately if signs or symptoms of hypersensitivity reactions develop, as a delay in stopping treatment may result in a life-threatening reaction. ( 5.2 ) • Hepatotoxicity has been

Dovato Black Box Warning

No black box warning on record for Dovato

Other warnings & precautions

Dovato Black Box Warning

No black box warning on record for Dovato

Other warnings & precautions